<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084551</url>
  </required_header>
  <id_info>
    <org_study_id>243-09-001</org_study_id>
    <secondary_id>JapicCTI-101053</secondary_id>
    <nct_id>NCT01084551</nct_id>
  </id_info>
  <brief_title>Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)</brief_title>
  <official_title>A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in
      patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg
      during a 13-week dose-titration and maintenance period. This is a multi-center, randomized,
      placebo-controlled, double-blind, 3-armed parallel group comparison study.

      Efficacy will be determined by investigating the superiority of SPM962 to placebo in terms of
      the primary efficacy variable, change in International Restless Legs Syndrome Rating Scale
      (IRLS) total score from baseline to the end of the dose-maintenance period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Restless Legs Syndrome Rating Scale (IRLS) Total Score</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Improvement</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI) Improvement</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>Change of PSQI from baseline to the end of dose-titration/dose-maintenance period.
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates &quot;no difficulty&quot; and 21 indicates &quot;severe difficulty&quot;. A decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each Item of IRLS (10 Items)</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of RLS Symptoms</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week* 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Duration of RLS Symptoms</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
    <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of RLS Symptoms in the Evening and Night</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Duration of RLS Symptoms in the Evening and Night in a Week</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
    <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Awakenings Due to RLS Symptoms in a Week</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
    <description>Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Sleep Time in a Week</measure>
    <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
    <description>Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Idiopathic Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>SPM 962 4.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPM 962 6.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>for 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPM 962</intervention_name>
    <description>once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
    <arm_group_label>SPM 962 4.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPM 962</intervention_name>
    <description>once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
    <arm_group_label>SPM 962 6.75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of SPM 962</intervention_name>
    <description>once a daily transdermal administration for 13 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose condition has been diagnosed as RLS by meeting all 4 of the
             International Restless legs Syndrome Study Group/ National Institute of Health
             (IRLSSG/NIH) criteria

          -  Patients who meet any of the following criteria relating to RLS treatment:

               -  Patients who have never received treatment for RLS

               -  Patients who have received treatment for RLS in the past and responded to L-dopa
                  or dopamine agonists (Response to other RLS medicines is irrelevant.)

          -  Patients who have an IRLS total score of &gt;=15 at baseline

          -  Patients who experience symptoms in the evening or during the night on at least two
             days a week within 14 days prior to commencement of study treatment

          -  Patients and their partners can practice contraception at the end of follow-up
             observation period or by 1 week after the end of treatment

        Exclusion Criteria:

          -  Patients who have previously participated in a clinical trial of SPM962 and taken the
             investigational product (IP)

          -  Patients with secondary RLS induced by renal impairment (uremia), iron deficiency
             anemia, drugs, pregnancy, etc.

          -  Patients who currently suffer, are at risk of developing, or have a history of sleep
             disorder such as sleep apnea syndrome, narcolepsy, and sleep attacks/sudden onset of
             sleep

          -  Patients who have concomitant diseases or symptoms which may affect the symptoms of
             RLS, such as polyneuropathy (including diabetic neuropathy), akathisia, claudication,
             varicoses, muscle fasciculation, painful legs and moving toes syndrome, radiculopathy
             and folate deficiency

          -  Patients who have other CNS diseases such as Parkinson's disease, dementia,
             progressive supranuclear paresis, multisystem atrophy, Huntington's Chorea,
             amyotrophic lateral sclerosis, and Alzheimer's disease

          -  Patients who have psychiatric conditions such as confusion, hallucination, delusion,
             and excitation, or patients who have abnormal behavior such as delirium, obsessive
             compulsive disorder, and impulse control disorder at the time of the screening test or
             baseline examination

          -  Patients whose SBP declines by at least 30 mmHg from supine to standing position based
             on the orthostatic hypotension assessment, or patients who develop orthostatic
             hypotension at baseline

          -  Patients who have a history of epilepsy, convulsion, etc

          -  Patients who have complications or a history of serious cardiac diseases or arrhythmia
             (eg, congestive heart failure of class 3 or 4 in the NYHA classification, second or
             third degree atrioventricular block, complete left bundle branch block, sick sinus
             syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to
             the screening test, or a complication of angina pectoris)

          -  Patients with arrhythmia who have been taking Class 1a antiarrhythmic drugs (eg.,
             quinidine, procainamide) or Class 3 antiarrhythmic drugs (eg., amiodarone, sotalol)

          -  Patients who have a serious ECG abnormality at the screening test and at the baseline
             examination

               -  Patients who show QTc intervals exceeding 450 ms in both ECGs in the screening
                  test

               -  Patients who have an average QTc interval from the two ECGs in the baseline
                  assessment that exceeds 470 ms (for females) or 450 ms (for males)

          -  Patients with congenital long QT syndrome

          -  Patients whose serum potassium level is &lt; 3.5mEq/L at the screening test

          -  Patients whose total bilirubin is &gt;= 3.0mg/dL, or whose AST(GOT) and ALT(GPT) are
             equal or more than 2.5 times the reference range of the clinical site (or &gt;= 100IU/L)
             at the screening test

          -  Patients whose BUN level is &gt;= 30mg/dL, or whose serum creatinine level is &gt;= 2.0mg/dL
             at the screening test

          -  Patients who have a history of allergy to topical agents such as transdermal patch

          -  Patients who are pregnant or nursing or who wish to become pregnant during the study
             period

          -  Patients who habitually drink alcohol or smoke excessively

          -  Patients who engage in evening shift work or other such shift work, or whose work or
             circumstances makes it difficult to maintain a regular period of sleep

          -  Patients who engage in hazardous work such as driving a vehicle, operating machinery,
             or working in a high location.

          -  Patients with autoimmune disease, chronic active hepatitis, or immune deficiency
             disorder

          -  Patients who have a complication or history of malignant neoplastic disease, or
             received treatment for the disease within 12 months prior to the screening test

          -  Patients who are unable to properly record information in a patient diary

          -  Patients who received other IPs within 12 weeks prior to commencement of study
             treatment

          -  Patients who have been judged by the investigator or the sub-investigator to be
             inappropriate for inclusion in the study for any other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>May 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0 mg/day for 13 weeks</description>
        </group>
        <group group_id="P2">
          <title>SPM 962 4.5</title>
          <description>started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
        </group>
        <group group_id="P3">
          <title>SPM 962 6.75</title>
          <description>started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0 mg/day for 13 weeks</description>
        </group>
        <group group_id="B2">
          <title>SPM 962 4.5</title>
          <description>started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
        </group>
        <group group_id="B3">
          <title>SPM 962 6.75</title>
          <description>started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="94"/>
            <count group_id="B4" value="284"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="15.3"/>
                    <measurement group_id="B2" value="50.7" spread="13.3"/>
                    <measurement group_id="B3" value="50.9" spread="13.7"/>
                    <measurement group_id="B4" value="51.7" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>International Restless Legs Syndrome Rating Scale (IRLS) Total Score</title>
        <description>Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>International Restless Legs Syndrome Rating Scale (IRLS) Total Score</title>
          <description>Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
          <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="8.2"/>
                    <measurement group_id="O2" value="-14.3" spread="8.9"/>
                    <measurement group_id="O3" value="-14.6" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Improvement</title>
        <description>CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Improvement</title>
          <description>CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with “much improved”</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with “very much improved”</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="41.9"/>
                    <measurement group_id="O3" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression (PGI) Improvement</title>
        <description>PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression (PGI) Improvement</title>
          <description>PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline.
The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with “much improved”</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with “very much improved”</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pittsburgh Sleep Quality Index (PSQI)</title>
        <description>Change of PSQI from baseline to the end of dose-titration/dose-maintenance period.
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates “no difficulty” and 21 indicates “severe difficulty”. A decrease in the scores means improvement.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pittsburgh Sleep Quality Index (PSQI)</title>
          <description>Change of PSQI from baseline to the end of dose-titration/dose-maintenance period.
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates “no difficulty” and 21 indicates “severe difficulty”. A decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.4"/>
                    <measurement group_id="O2" value="-3.1" spread="3.2"/>
                    <measurement group_id="O3" value="-3.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Each Item of IRLS (10 Items)</title>
        <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Each Item of IRLS (10 Items)</title>
          <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-4 (RLS discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (RLS discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (need to move around due to RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (need to move around due to RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (discomfort relief by moving around)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (discomfort relief by moving around)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of RLS as a whole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of RLS as a whole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (RLS symptoms frequency)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (RLS symptoms frequency)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (average duration of RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (average duration of RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of sleep disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of sleep disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (tiredness or sleepiness during the day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (tiredness or sleepiness during the day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of the impact on daily affairs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of the impact on daily affairs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of mood disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of mood disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of RLS Symptoms</title>
        <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week* 100%</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of RLS Symptoms</title>
          <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week* 100%</description>
          <population>FAS, LOCF</population>
          <units>percentage of days with RLS symptom</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" spread="20.8"/>
                    <measurement group_id="O2" value="85.4" spread="20.5"/>
                    <measurement group_id="O3" value="83.2" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="40.9"/>
                    <measurement group_id="O2" value="35.8" spread="38.6"/>
                    <measurement group_id="O3" value="36.8" spread="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Duration of RLS Symptoms</title>
        <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of RLS Symptoms</title>
          <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
          <population>FAS, LOCF</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="4.7"/>
                    <measurement group_id="O2" value="-3.7" spread="4.6"/>
                    <measurement group_id="O3" value="-4.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of RLS Symptoms in the Evening and Night</title>
        <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation * 100%.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of RLS Symptoms in the Evening and Night</title>
          <description>Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation * 100%.</description>
          <population>FAS, LOCF</population>
          <units>percentage of days/week with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="24.2"/>
                    <measurement group_id="O2" value="83.3" spread="20.8"/>
                    <measurement group_id="O3" value="79.5" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="41.0"/>
                    <measurement group_id="O2" value="34.6" spread="38.2"/>
                    <measurement group_id="O3" value="31.8" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Duration of RLS Symptoms in the Evening and Night in a Week</title>
        <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of RLS Symptoms in the Evening and Night in a Week</title>
          <description>Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.</description>
          <population>FAS, LOCF</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.1"/>
                    <measurement group_id="O2" value="-1.8" spread="2.5"/>
                    <measurement group_id="O3" value="-1.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Awakenings Due to RLS Symptoms in a Week</title>
        <description>Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation * 100%.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (week 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Awakenings Due to RLS Symptoms in a Week</title>
          <description>Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation * 100%.</description>
          <population>FAS, LOCF</population>
          <units>percentage of days/week with awakening</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="35.9"/>
                    <measurement group_id="O2" value="22.6" spread="31.3"/>
                    <measurement group_id="O3" value="28.3" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="31.7"/>
                    <measurement group_id="O2" value="7.7" spread="20.5"/>
                    <measurement group_id="O3" value="7.5" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Sleep Time in a Week</title>
        <description>Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.</description>
        <time_frame>Baseline, the end of dose-titration/dose-maintenance period (weeks 13)</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once a daily transdermal administration for 13 weeks</description>
          </group>
          <group group_id="O2">
            <title>SPM 962 4.5</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
          </group>
          <group group_id="O3">
            <title>SPM 962 6.75</title>
            <description>Once a daily transdermal administration of SPM 962 started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Sleep Time in a Week</title>
          <description>Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.</description>
          <population>FAS, LOCF</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.8"/>
                    <measurement group_id="O2" value="0.5" spread="1.1"/>
                    <measurement group_id="O3" value="0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0 mg/day for 13 weeks</description>
        </group>
        <group group_id="E2">
          <title>SPM 962 4.5</title>
          <description>started at 2.25 mg/day to 4.5 mg/day for 13 weeks</description>
        </group>
        <group group_id="E3">
          <title>SPM 962 6.75</title>
          <description>started at 2.25 mg/day to 6.75 mg/day for 13 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(13.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>VIIth Nerve Paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA(13.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E2" events="37" subjects_affected="32" subjects_at_risk="95"/>
                <counts group_id="E3" events="48" subjects_affected="41" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E2" events="41" subjects_affected="40" subjects_at_risk="95"/>
                <counts group_id="E3" events="50" subjects_affected="47" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

